Tango Therapeutics President Crystal Adam Exercises Options, Sells Shares

What Happened

• Crystal Adam, President, Research & Development at Tango Therapeutics (TNGX), exercised 27,000 option shares and sold 27,000 shares on September 1, 2026. The exercise required $140,400 (27,000 shares × $5.20 exercise price). The sale of 27,000 shares generated roughly $603,909 (weighted average sale price $22.37).

Key Details

• Transaction date: 2026-09-01 (reported on Form 4 filed 2026-09-03). No late filing indicated in the provided filing.
• Exercise: 27,000 shares acquired at $5.20 each = $140,400.
• Sale: 27,000 shares sold, weighted average price $22.37, total proceeds ≈ $603,909. Report notes sale prices ranged $22.08–$22.86 per share (full per-price breakdown available on request).
• Additional derivative line: the filing also lists a 27,000-share derivative disposition at $0.00 (no value shown); the filing does not add further detail on that line.
• Footnotes: Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted October 27, 2025 (F1). The option vests over four years (25% on Feb 27, 2024, then monthly over 36 months) (F3).
• Shares owned after the transaction: not specified in the data you provided.

Context

• This is effectively an exercise-and-sell (cashless-style) event: options were exercised and an equal number of shares were sold the same day under a 10b5-1 plan, producing net proceeds after exercise costs. Such transactions are commonly used to monetize vested option shares and, when done under a 10b5-1 plan, are pre-scheduled trading arrangements rather than ad-hoc trades.